Royalty Pharma (RPRX) Profit After Tax (2019 - 2026)
Royalty Pharma (RPRX) posted Profit After Tax of $294.7 million for Q1 2026, up 249.34% sequentially from -$197.3 million in Q4 2025, and up 23.12% YoY from $239.3 million in Q1 2025.
Royalty Pharma (RPRX) Profit After Tax (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Profit After Tax for 8 years, with the latest figure at $294.7 million in Q1 2026.
- Quarterly Profit After Tax rose 23.12% year-over-year to $294.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $632.2 million (down 56.07% YoY) and the FY2025 annual result came in at $770.9 million, down 10.25% from the prior year.
- Profit After Tax rose to $294.7 million in Q1 2026 per RPRX's latest filing, from -$197.3 million in the prior quarter.
- Over five years, Profit After Tax peaked at $1.1 billion in Q4 2023 and troughed at -$268.9 million in Q4 2022.
- A 5-year average of $261.1 million and a median of $208.2 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax tumbled 3501.47% in 2022, then surged 4909.4% in 2025.
- Over 5 years, Profit After Tax stood at -$268.9 million in 2022, then soared by 494.12% to $1.1 billion in 2023, then sank by 80.35% to $208.2 million in 2024, then slumped by 194.77% to -$197.3 million in 2025, then soared by 249.34% to $294.7 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $294.7 million, -$197.3 million, and $444.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.49 Mn |
| Mar 31, 2026 | 294.69 Mn |
| Dec 31, 2025 | -197.33 Mn |
| Sep 30, 2025 | 444.21 Mn |
| Jun 30, 2025 | 90.64 Mn |
| Mar 31, 2025 | 239.35 Mn |
| Dec 31, 2024 | 208.21 Mn |
| Sep 30, 2024 | 806.36 Mn |
| Jun 30, 2024 | 185.33 Mn |
| Mar 31, 2024 | 4.78 Mn |
| Dec 31, 2023 | 1.06 Bn |
| Sep 30, 2023 | 72.11 Mn |
| Jun 30, 2023 | 227.63 Mn |
| Mar 31, 2023 | 509.09 Mn |
| Dec 31, 2022 | -268.85 Mn |
| Sep 30, 2022 | 142.65 Mn |
| Jun 30, 2022 | 491.60 Mn |
| Mar 31, 2022 | 128.08 Mn |
| Dec 31, 2021 | 7.90 Mn |
| Sep 30, 2021 | 221.80 Mn |